To determine whether targeting the BMP pathway is therapeutic in ACVR1 mutant DIPGs, we sought to inhibit BMP signaling by expressing exogenous Noggin, an extracellular antagonist of the BMP pathway, along with ACVR1 R206H, PDGFA, and p53 loss at tumor initiation. Here, NOG is linked to neoplasm.